Home

DAVID M STACK

CIK 1204788 · CEO and Chairman · last filed 2023-06-16

DAVID M STACK is a CEO and Chairman who has filed 123 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for PCRX, was dated Jun 16, 2023. Across all open-market trades the lifetime net is −$50.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions. 71 SEC filings were submitted jointly with Pacira BioSciences, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.43M

Companies

5

Total Filings

123

Lifetime Open-Market Net

-$50.01M

Filer Profile

Reported Address
THE MEDICINES CO
8 CAMPUS DRIVE
PARSIPPANY, NJ 07054
Related Filers
Pacira BioSciences, Inc. — 71 joint filings, latest 2023-06-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PCRX CEO and Chairman 205,077 $26.35 $5.40M -$45.50M 64 2023-06-16
CHIASMA, INC (CHMA) Delisted Director 0 $3.76 $0 $106.9K 7 2021-08-05
AMRN Director 2,000 $13.63 $27.3K -$4.09M 15 2021-06-16
BIOCLINICA INC (UWBK) Delisted Director 89,150 — — -$530.2K 31 2010-11-19
Molecular Insight Pharmaceuticals, Inc. (MIPI) Delisted Director — — — $0 4 2010-05-17

Recent Filings

123 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-16 PCRX Grant (A) +32,700 $0 EDGAR
2023-06-07 PCRX Notice (144) −5,326 -$201.7K EDGAR
2023-06-07 PCRX Sell (S) −10,384 -$398.9K EDGAR
2023-06-06 PCRX Notice (144) −5,058 -$197.2K EDGAR
2022-06-08 PCRX Mixed −4,293 -$1.56M EDGAR
2022-05-02 PCRX Exer (M) +22,500 $243.2K EDGAR
2022-04-05 PCRX Exer (M) +22,500 $243.2K EDGAR
2022-01-27 PCRX Exer (M) +13,670 $147.8K EDGAR
2022-01-13 PCRX Exer (M) +15,000 $162.2K EDGAR
2021-11-18 PCRX Exer (M) +15,000 $162.2K EDGAR
Showing 1–10 of 123
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.